AnselmFox t1_iybyggf wrote on November 30, 2022 at 6:43 AM

Reply to comment by SingularityPrime in Alzheimer's drug lecanemab hailed as momentous breakthrough by Methoszs

No “they” don’t. The phase 3 shows almost no real change in symptoms vs control groups…1.6 vs 1.2 change in score (out of 18) on Alzheimer’s battery used (CDRSB) and over an 18 months— (calling that a 27% change in symptom progression is disingenuous- yes it’s “statistically significant” but in reality that’s the difference between a 1/2 point in scoring on some domain of the battery over a yr and a 1/2 of treatment) and nowhere is it suggested in the actual data that there are “19 months more of independent living”— maybe the stock prospectus says that though! It’s a crock of shit. This is a media blitz. Anyway don’t take my word the study is published if you can sift through the bias in it

CatumEntanglement t1_iycaabv wrote on November 30, 2022 at 9:28 AM

Thank you, thank you, thank you. As someone on the research side of human neurodegenerative diseases, this drug is, as you say...a crock of shit.

As an aside, all patients classified with idopathic/sporadic AD (which are 95% of cases) showed no change in the CDRSB scoring. This drug is no better than a placebo IMO. A very expensive ($30k-50k) placebo that has to be infused into the CSF and causes brain bleeds in 17% of patients. The only true significant thing this drug does is give people brain bleeds.